1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow tanimilast: new trials by email Literature Review of tanimilast trials Research Report on tanimilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 3973 | 2021-07-12 | 2026-02-02 |
Bronchitis, Chronic (1) · Pulmonary Disease, Chronic Obstructive (1)
Chiesi Farmaceutici S.p.A. (1)
Argentina (1) · Austria (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Chile (1) · Croatia (1) · Czechia (1) · Estonia (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Latvia (1) · Mexico (1) · Netherlands (1)
2023 (1)